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An investigation of infectious intestinal disease in England included examination of feces
for Vero cytotoxin-producing Escherichia coli (VTEC). Using DNA probe hybridization 27
VTEC strains were identified, 12 were from cases, and of these three belonged to
serogroup O157. The remaining 15 strains were isolated from controls. The strains were
confirmed biochemically as E. coli, they were serotyped and characterized according to
their toxin production, the presence of sequences encoding intimin (eae) and enterohe-
molysin was determined and resistance to antimicrobial agents was determined. Six of
the nine cases with non-O157 VTEC were less than 16 years old, only two of the 15 controls
were under 16. Infection with more than one micro-organism was also considered.
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Vero cytotoxin-producing Escherichia coli (VTEC)
are associated with human disease including mild
diarrhea, severe bloody diarrhea with abdominal
pain and hemolytic uremic syndrome (HUS) [1].
These organisms are also described as Shiga toxin-
producing E. coli (STEC). The most important
serogroup in the United Kingdom is O157 but
more than 100 serotypes of E. coli have been shown
to produce Vero cytotoxins. Unlike VTEC O157,
few studies in the UK have investigated VTEC of
other serogroups [2,3]. A major investigation was
undertaken to determine the true incidence of
infectious intestinal disease (IID) in England and
to estimate the incidence in the community of
gastrointestinal disease with a microbiological
cause [4]. Between August 1993 and January
1996 fecal samples from cases and controls in
two study components were examined; one was
a community cohort (n¼ 1316) and the other a
General Practice (GP) case–control component
(n¼ 5157). Cases of IID in the GP case–control
component generally had more severe symptoms
than those in the community cohort since they
were a selected subset from the community who
had sought medical advice. The overall microbio-
logical findings and rates of IID have been
reported [5,6] but details of the properties of spe-
cific organisms were not included. The IID study
included examination for six groups of pathogenic
or potentially pathogenic groups of E. coli. The
results of studies with VTEC belonging to all
serogroups are reported here.
Full details of the methods have been published
in the report of the IID Study [4]. Briefly, fecal
suspensions were prepared for direct hybridiza-
tion and a sweep of representative coliform
growth was also hybridized using a mixture of
fluorescein-labeled VT1 and VT2 probes [4,7].
Probe-positive colonies were identified and hybri-
dized with individual VT1 and VT2 probes [8,9].
Isolates were confirmed biochemically as E. coli
and serotyped as described previously [10]. Resis-
tance to antimicrobial agents was determined by
an agar dilution method [11]. The final plate con-
centrations of the drugs were (mg/L): ampicillin,
8; chloramphenicol, 8; gentamicin, 4; kanamycin,
16; streptomycin, 16; sulfathiazole, 64; tetracy-
clines, 8; trimethoprim, 2; furazolidone, 8; nalidixic
acid, 16; ciprofloxacin, 0.125 and 1.0. The presence
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of sequences encoding intimin (eae) and enterohe-
molysin was determined with DNA probes
[12,13]. For detection of enterohemolysin produc-
tion, strains were streaked on sheep blood agar
(5% sheep blood, washed three times in sterile
phosphate-buffered saline added to L agar base)
for single colonies and incubated at 37 8C over-
night. The plates were examined for hemolysis
immediately after incubation and after 4–6 h at
room temperature.
A total of 27 VTEC strains was isolated during
the study [4,6]. Three belonged to serogroup O157
and were isolated from cases in the GP case–
control component. Fifteen non-O157 VTEC cases
were also identified in this part of the study; six
(0.2% of samples) were from cases and nine (0.4%
of samples) from controls (Table 1). In the commu-
nity cohort component of the study, the nine non-
O157 VTEC comprised three that were isolated
from cases (0.4% of samples) and six from controls
(1.1% of samples). Six of the nine cases with
non-O157 VTEC from the two components of
the study were children (under 16 years) of which
three were under 5 years, whereas only two of the
15 controls were children, both under 5 years. The
numbers in this study were small but the results
suggested that carriage of non-O157 VTEC in
healthy individuals may be higher in adults than
in young children (P¼ 0.021, Fisher exact test).
Seven of the individuals infected with non-O157
VTEC lived in rural areas and the other 17 were
from urban or suburban areas. Fifteen of the 24
non-O157 VTEC strains were detected between
September and December. Eight of the 24 persons
with non-O157 VTEC had mixed infections,
including five of the six cases from the GP case–
control component (two with Campylobacter, one
each with Yersinia, rotavirus and adenovirus,
respectively; one cohort-case was also positive
for Clostridium perfringens enterotoxin and one





(years) VT1 VT2 eae CVD 419
Hemolysin
production
O157:H7a GP case 2 – þ þ þ þ
O157:H7a GP case 18 þ þ þ þ þ
O157:H7a GP case 23 – þ þ þ þ
O52:H25 GP case 4 – þ – – –
O?:H2 GP case 2 þ – þ þ þ
O?:H10 GP case 5 – þ – – –
O?:H10 GP case 62 þ þ – þ þ
O?:H19 GP case 67 þ – – – –
O rough: H- GP case 56 – þ – – –
O82:H2 GP control 3 þ þ – þ þ
O91:H- GP control 54 þ – – þ V
O118:H1 GP control 44 – þ – – –
O128ab:H2 GP control 28 þ þ – þ þ
O128ab:H2 GP control 30 þ þ – þ þ
O146:H21 GP control 66 þ þ – þ þ
O162:H6 GP control 67 þ þ – – –
O162:H8 GP control 68 þ þ – – V
O?:H- GP control 65 þ þ – – –
O26:H11 Cohort case 8 þ – þ þ þ
O91:H10 Cohort case 1 – þ – – –
O rough:H- Cohort case 12 þ þ – þ V
O115:H7 Cohort control 2 þ – – – –
O128 ab: H2 Cohort control 53 þ þ – þ þ
O146:H21 Cohort control 34 þ þ – þ V
O?: H18 Cohort control 39 þ þ – þ V
O?: H21 Cohort control 46 þ – – þ þ
O?: H- Cohort control 39 – þ – þ þ
aThe phage types of the three E. coli O157:H7 strains were 2,14 and 32.
V¼variable production.
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cohort-control and one GP control each had Yersi-
nia co-infection) [4].
Properties of the 27 VTEC strains are listed in
Table 1. The three VTEC O157 isolates carried the
VT2 and eae genes and were also enterohemolysin
probe positive. Fourteen of the non-O157 VTEC
belonged to recognized serotypes but eight were
untypable using the current scheme that identifies
173 O serogroups. Serotyping was the method
chosen for examining the E. coli isolated in the
IID study. However, DNA methods have devel-
oped since that time, for example, it may be pos-
sible to study the non-serotypable isolates using
pulsed field gel electrophoresis but H types can be
readily used to distinguish between O? strains. Six
combinations of VT toxin genes were detected and
18 of the 24 non-O157 VTEC possessed the VT1
gene. This contrasts with VTEC O157 strains iso-
lated in England and Wales, of which 76% have the
VT2 gene only [7]. Only two of the non-O157 VTEC
carried the eae gene, both were isolated from cases
(Table 1). Fourteen of the 24 non-O157 VTEC
hybridized with the enterohemolysin probe
CVD 419 and produced hemolysin. One strain
was hemolytic but negative with the CVD 419
probe. Only two of the VTEC strains were resistant
to antimicrobial agents: one, serotype O115:H7
was resistant to streptomycin and tetracyclines
and the second strain, serotype O52:H25 was resis-
tant to ampicillin, kanamycin, streptomycin, sul-
fathiazole, tetracylines and trimethoprim. This
result contrasted with other studies of E. coli
strains such as the enteroaggregative E. coli (EAg-
gEC) isolated in the IID study. One hundred and
fourteen of the 206 EAggEC strains (55%) were
resistant to one or more antimicrobial agents
(L.E.P., unpublished observations). In a recent
study of 3429 VTEC O157 strains 20% were resis-
tant to one agent tested but only 1.3% were resis-
tant to four or more drugs [7].
Several studies have shown that certain VTEC
strains are associated with severe human disease
[1]. This subset of VTEC, known as enterohemor-
rhagic E. coli (EHEC), is linked with bloody diar-
rhea and HUS and includes strains of serogroup
O157 and non-O157 serogroups such as O26,
O1O3, O111 and O145 [14]. Almost all these EHEC
strains have the eae gene and produce enterohe-
molysin. The IID study examined individuals pre-
senting to GPs or those with intestinal disease in
the community. More severe cases of VTEC infec-
tion, such as those with HUS, may not have been
investigated as part of this study as persons with
severe symptoms were more likely to be hospita-
lized. One child with VTEC O26 was identified
and this strain was eae and enterohemolysin posi-
tive: these properties are found in most VTEC O26
[15]. In a recent report of VTEC infections in
England and Wales between 1995 and 1998 11
non-O157 VTEC strains were characterized. Three
of the individuals had bloody diarrhea, five had
non-bloody diarrhea and one had HUS [7]. Eight of
the 11 isolates were eae positive and seven hybri-
dized with the CVD 419 probe for the enterohe-
molysin gene. Five of the isolates were O26:H11
including the one from the HUS case.
The IID study is one of the few performed in
Britain to provide information on VTEC other than
specifically serogroup O157. The small numbers
identified means that it is difficult to draw con-
clusions on the statistical implications of there
being a higher proportion of VTEC among controls
than cases. These strains were not a significant
cause of IID and were carried by several indivi-
duals, mainly adults that did not have symptoms
of gastro-intestinal disease. The relative impor-
tance of VTEC of serogroup O157 compared with
those of other serogroups appears to vary consid-
erably between countries, including those with
common borders such as Belgium and Germany.
Studies have shown that the frequencies of VTEC
infections in mainland Europe are generally lower
than those seen in the UK and the USA [1,16–18].
where the vast majority of reports are of VTEC
O157 infections. Pie´rard et al. [16] reported that in
four cases of HUS seen during a study lasting over
five years, three of the four were associated with
VTEC O157 whilst the sample from the fourth case
was polymerase chain reaction-positive without a
culturable isolate. However, cases of HUS can be
caused by non-O157 VTEC and therefore vigilance
is required. For patients with HUS or bloody
diarrhea, whose stools are negative for E. coli
O157, Salmonella and Campylobacter, fecal speci-
mens should be examined for non-O157 VTEC.
This should allow further assessment of the role of
these organisms in human disease.
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